# Progyny share price today (Progyny, Inc., PGNY)

> Progyny, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 19% of past readings. PGNY · Healthcare · Healthcare Plans · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/pgny

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: $29.06 (+55.3% in a year)
- P/E: 32.0× (lower than 81% of the last 4.6 years)
- Revenue (Jun 2026): $351 M (+5.3% on a year ago)
- Profit (Jun 2026): $28.1 M (+63.9% on a year ago)
- Operating margin: 11.4% (+4.1 points on a year ago)
- ROE: 11%, FY25
- ROIC: 32.4%, against a 9.3% cost of capital: +23.1 points

The main question: the share price moved +55.3% in a year while yearly earnings per share moved +14.0%. The difference came from the market paying a higher multiple. ## What is the Progyny share price today? Progyny, Inc.'s share price was $29.06 at the close on 3 November 2026. It has been rising for 18 weeks. That is 19.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $16 and $32, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 7 years the share price moved +58% while the S&P 500 moved +146%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Progyny pay? Progyny, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Progyny on? Progyny is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Progyny profitable? Progyny, Inc. earned $28.1 M of net profit in the Jun 2026 quarter, +63.9% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY25 profit was $58.5 M. Over 4 years profit has grown −2.9% a year on average. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned $17.1 M. For the full year, FY25 profit was $58.5 M (+7.7% on the year before). Why profit moved: revenue changed +5.3% on a year earlier and the margin moved +4.1 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +44.1% and revenue +5.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Progyny make, and is it growing? Progyny, Inc. reported $351 M of revenue in the Jun 2026 quarter, +5.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 26.7% a year on average. The last full year, FY25, came in at $1.3 B. The last four reported quarters add to $1.3 B. FY25 revenue was $1.3 B, +10.4% on the year before. Recent pace: the last four quarters grew +5.7% on average, against 26.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.5%, against +7.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +48.0%, against +11.9% a year (accelerating). ## How much of every $100 of sales does Progyny keep? Progyny, Inc.'s operating margin was 11.4% in the Jun 2026 quarter, 4.1 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 3.0% and 7.2%. The latest quarter is above every full year in that period. Across 5 years it has been between 3.0% and 7.2%, and FY25's 7.2% is the highest of them. Why the margin moved: operating margin changed +4.1 percentage points on the year while gross margin changed +1.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Progyny's profit turning into cash? Over the last 3 years, 331% of Progyny, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $210 M of operating cash against $58.5 M of profit. After $18.4 M of spending on assets, $192 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Progyny's cash go? Progyny, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $27.5 M on assets over the last 3 years. Averaged over those years that is 0.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $27.5 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Progyny's P/E ratio, and how does it compare with its own history? Progyny, Inc.'s P/E is 32.0×, near the low end of its own history: it has been lower only 19% of the time. Its usual P/E (the middle reading) is 43.4×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +14.0% while the price moved +55.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −3.1% a year; about +20.9% a year came from earnings growth and about −24.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Progyny business getting better or worse? Progyny, Inc.'s business is getting better. Profit growth hit its low 4 quarters ago at −14.3% and has recovered to +48.0%, with ROCE rising at 23.6%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Progyny earn on its capital? Progyny, Inc. earned a ROE of 11% in FY25. That is up from a low of 8% in FY22. Its return on capital used (ROIC) is 23.1 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 4.5% net margin and 1.74× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 4.5% net margin × 1.74× asset turnover × 1.44× leverage (assets divided by equity) ≈ 11.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 32.4% − 9.3% = +23.1 percentage points. The 9.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 32.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 25.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Progyny have too much debt? Progyny, Inc. has total debt of $27.0 M against shareholder equity of $453 M as of Jun 2026, so its debt is 0.06× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.05 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Progyny shareholding pattern? 6.9% of Progyny, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Progyny from balance-sheet trouble? For Progyny, Inc., the Z-score is 7.63. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 7.63 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Progyny rank in its industry? 74.9 out of 100, rank 1 of 11 in Healthcare Plans, with 81% of the evidence available. Progyny, Inc. scores 74.9 out of 100 against the 11 companies it is compared with in Healthcare Plans, ranking 1. Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. The four parts add up to the total exactly: 27.1 + 21.1 + 13.3 + 13.4 = 74.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Progyny compared with? Progyny ranks 1 of 11 Healthcare Plans companies on the 4-Factor Sector Score, with 74.9 out of 100. 1. Progyny, Inc. this page PGNY · turning · Most evidence points up · 81% evidence 74.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 5.6% · Profit 47.2% · Operating margin change 4.1 points · 83% evidence Capital efficiency 21.1/25 · ROCE 25.2% · Operating margin 11.4% · 76% evidence Valuation 13.3/20 · P/E 28.7× · PEG 0.51 · 65% evidence Relative strength 13.4/20 · Lead over its industry 1.9% · Lead over S&P 500 12.5% · 1 year 29.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 27.1 + 21.1 + 13.3 + 13.4 = 74.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [The Cigna Group](https://www.sectoralpha.in/us/stocks/ci) CI · turning · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 7.8% · Profit 27.9% · Operating margin change 0.3 points · 83% evidence Capital efficiency 13.8/25 · ROCE 11.8% · Operating margin 4% · 76% evidence Valuation 15.6/20 · P/E 11.4× · PEG 0.35 · 65% evidence Relative strength 7.4/20 · Lead over its industry -10.8% · Lead over S&P 500 0.2% · 1 year 11.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 20.4 + 13.8 + 15.6 + 7.4 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [UnitedHealth Group Incorporated](https://www.sectoralpha.in/us/stocks/unh) UNH · turning · Evidence leans up · 65% evidence 51.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 3.4% · Profit -9.7% · Operating margin change 2 points · 71% evidence Capital efficiency 13.8/25 · ROCE n/a · Operating margin 5.8% · 30% evidence Valuation 13.1/20 · P/E 20.7× · PEG 0.72 · 65% evidence Relative strength 9.9/20 · Lead over its industry -2.3% · Lead over S&P 500 8.1% · 1 year 24.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 13.8 + 13.1 + 9.9 = 51.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 4. [Humana Inc.](https://www.sectoralpha.in/us/stocks/hum) HUM · breaking out · Evidence leans down · 62% evidence 49.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.1/35 · Revenue 18.3% · Profit -18.9% · Operating margin change -0.1 points · 62% evidence Capital efficiency 10.7/25 · ROCE n/a · Operating margin 3.5% · 30% evidence Valuation 6.4/20 · P/E 37.3× · PEG 2.13 · 65% evidence Relative strength 17.9/20 · Lead over its industry 22.9% · Lead over S&P 500 33.4% · 1 year 65.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 14.1 + 10.7 + 6.4 + 17.9 = 49.1 · What this means: Relative strength against the index is 33.4%, and revenue and profit growth are weak. 5. [Elevance Health, Inc.](https://www.sectoralpha.in/us/stocks/elv) ELV · turning · Evidence leans down · 77% evidence 40.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 3.6% · Profit -7.1% · Operating margin change 0.7 points · 71% evidence Capital efficiency 8.4/25 · ROCE 3.2% · Operating margin 4.2% · 76% evidence Valuation 8.6/20 · P/E 16.4× · PEG 2.05 · 65% evidence Relative strength 9.4/20 · Lead over its industry -3.5% · Lead over S&P 500 7.3% · 1 year 30.2% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.5 + 8.4 + 8.6 + 9.4 = 40.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Molina Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/moh) MOH · turning · Evidence leans down · 67% evidence 40.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue -1.8% · Profit -105.4% · Operating margin change -0.2 points · 71% evidence Capital efficiency 7.9/25 · ROCE 4.8% · Operating margin 1% · 76% evidence Valuation 11.5/20 · P/E -205.2× · PEG n/a · 15% evidence Relative strength 13.0/20 · Lead over its industry -0.3% · Lead over S&P 500 10.2% · 1 year 36.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 8.3 + 7.9 + 11.5 + 13 = 40.7 · What this means: Relative strength against the index is 10.2%, and revenue and profit growth are weak. 7. [CVS Health Corporation](https://www.sectoralpha.in/us/stocks/cvs) CVS · quiet · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 7.4% · Profit 8.8% · Operating margin change 1.1 points · 83% evidence Capital efficiency 10.2/25 · ROCE 7.3% · Operating margin 3.9% · 76% evidence Valuation 4.4/20 · P/E 27× · PEG 4.83 · 65% evidence Relative strength 5.0/20 · Lead over its industry -9.6% · Lead over S&P 500 0.3% · 1 year 15.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 18.8 + 10.2 + 4.4 + 5 = 38.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Oscar Health, Inc.](https://www.sectoralpha.in/us/stocks/oscr) OSCR · turning · Too little evidence to rank firmly · 45% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 42.8% · Profit n/a · Operating margin change 16 points · 40% evidence Capital efficiency 11.7/25 · ROCE n/a · Operating margin 8% · 30% evidence Valuation 10.3/20 · P/E 15.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 30.5% · Lead over S&P 500 40.8% · 1 year 82.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22 + 11.7 + 10.3 + 20 = 64 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Clover Health Investments, Corp.](https://www.sectoralpha.in/us/stocks/clov) CLOV · quiet · Too little evidence to rank firmly · 45% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 54% · Profit n/a · Operating margin change 6 points · 40% evidence Capital efficiency 9.6/25 · ROCE n/a · Operating margin 3.8% · 30% evidence Valuation 11.2/20 · P/E -150.3× · PEG n/a · 15% evidence Relative strength 12.6/20 · Lead over its industry 14.1% · Lead over S&P 500 23.1% · 1 year 60.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.7 + 9.6 + 11.2 + 12.6 = 55.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Centene Corporation](https://www.sectoralpha.in/us/stocks/cnc) CNC · turning · Too little evidence to rank firmly · 45% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 12.9% · Profit -349.7% · Operating margin change 3.9 points · 40% evidence Capital efficiency 11.1/25 · ROCE n/a · Operating margin 3.8% · 30% evidence Valuation 10.9/20 · P/E -6.2× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry 12.3% · Lead over S&P 500 22.8% · 1 year 79.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.7 + 11.1 + 10.9 + 12.1 = 53.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 11. [Alignment Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/alhc) ALHC · basing · Too little evidence to rank firmly · 45% evidence 36.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Healthcare Plans](https://www.sectoralpha.in/us/sectors/healthcare-plans), all 11 compared on one page. ## Which companies are close to Progyny in size? Progyny is the 10th largest of 11 Healthcare Plans companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Humana Inc., Centene Corporation, Molina Healthcare, Inc., Oscar Health, Inc. and Clover Health Investments, Corp. Just below it: Alignment Healthcare, Inc. ### Healthcare Plans companies close in size

1. [Humana Inc.](https://www.sectoralpha.in/us/stocks/hum) $50.2 billion
2. [Centene Corporation](https://www.sectoralpha.in/us/stocks/cnc) $33.4 billion
3. [Molina Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/moh) $10.8 billion
4. [Oscar Health, Inc.](https://www.sectoralpha.in/us/stocks/oscr) $10 billion
5. [Clover Health Investments, Corp.](https://www.sectoralpha.in/us/stocks/clov) $2.3 billion
6. Progyny, Inc. $2.2 billion
7. [Alignment Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/alhc) $1.5 billion

[All 11 Healthcare Plans companies, largest first](https://www.sectoralpha.in/us/sectors/healthcare-plans#all-companies)

### Companies close in size in other industries

1. [NETSTREIT Corp.](https://www.sectoralpha.in/us/stocks/ntst) $2.3 billion · REIT - Retail
2. [Intuitive Machines, Inc.](https://www.sectoralpha.in/us/stocks/lunr) $2.3 billion · Aerospace & Defense
3. Progyny, Inc. $2.3 billion
4. [Enterprise Financial Services Corp](https://www.sectoralpha.in/us/stocks/efsc) $2.3 billion · Banks - Regional
5. [TIC Solutions, Inc.](https://www.sectoralpha.in/us/stocks/tic) $2.3 billion · Specialty Business Services

## What else do people ask about Progyny? ### What were Progyny's latest quarterly results? Progyny, Inc. reported revenue of $351 M and net profit of $28.1 M for the Jun 2026 quarter. Revenue rose 5.3% and profit rose 63.9% compared with a year earlier. Earnings per share were $0.34. The operating margin was 11.4%, 4.1 percentage points higher than a year earlier (as of 3 November 2026). ### What is Progyny's market cap? Progyny, Inc.'s market capitalisation is $2.2 B at a stock price of $29.06. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Progyny performing? Progyny, Inc.'s share price has been rising for 18 weeks. In its latest quarter, revenue rose 5.3% and profit rose 63.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 1 week running (as of 3 November 2026). ### Will Progyny's stock price go up? This page does not forecast Progyny, Inc.'s stock price. What it shows instead: the stock price is $29.06, and it has been rising for 18 weeks. Its P/E of 32.0× is higher than 19% of its own last 5 years (as of 3 November 2026). ### Where is Progyny in its business cycle? Progyny, Inc.'s FY25 operating margin was 7.2%, against a 5-year range of 3.0% to 7.2%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 11.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Progyny story? The main question: the share price moved +55.3% in a year while yearly earnings per share moved +14.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Progyny a stock worth studying right now? What the numbers show: Progyny, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 19% of past readings. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.